A detailed history of Redhawk Wealth Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Redhawk Wealth Advisors, Inc. holds 5,199 shares of VRTX stock, worth $2.52 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
5,199
Previous 6,270 17.08%
Holding current value
$2.52 Million
Previous $2.62 Million 7.02%
% of portfolio
0.4%
Previous 0.45%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

SELL
$392.81 - $485.53 $420,699 - $520,002
-1,071 Reduced 17.08%
5,199 $2.44 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $2,446 - $2,676
-6 Reduced 0.1%
6,270 $2.62 Million
Q4 2023

Jan 12, 2024

BUY
$343.0 - $410.68 $221,578 - $265,299
646 Added 11.47%
6,276 $2.55 Million
Q3 2023

Oct 13, 2023

BUY
$338.18 - $362.46 $53,094 - $56,906
157 Added 2.87%
5,630 $1.96 Million
Q2 2023

Jul 13, 2023

BUY
$314.42 - $351.91 $282,978 - $316,719
900 Added 19.68%
5,473 $1.93 Million
Q1 2023

Apr 28, 2023

BUY
$283.23 - $323.1 $41,634 - $47,495
147 Added 3.32%
4,573 $1.44 Million
Q4 2022

Feb 10, 2023

BUY
$285.76 - $321.48 $58,580 - $65,903
205 Added 4.86%
4,426 $1.28 Million
Q3 2022

Oct 27, 2022

BUY
$273.83 - $305.53 $1.16 Million - $1.29 Million
4,221 New
4,221 $1.22 Million
Q4 2020

Jan 26, 2021

SELL
$207.01 - $276.09 $322,935 - $430,700
-1,560 Closed
0 $0
Q3 2020

Nov 03, 2020

BUY
$255.65 - $303.1 $16,361 - $19,398
64 Added 4.28%
1,560 $425,000
Q2 2020

Jul 14, 2020

SELL
$225.48 - $295.8 $19,616 - $25,734
-87 Reduced 5.5%
1,496 $434,000
Q1 2020

Apr 14, 2020

BUY
$199.77 - $247.81 $316,235 - $392,283
1,583 New
1,583 $377,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $125B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Redhawk Wealth Advisors, Inc. Portfolio

Follow Redhawk Wealth Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redhawk Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Redhawk Wealth Advisors, Inc. with notifications on news.